a r t I C l e S both overall variant burden as well as specific variants, with a wide range of neurodevelopmental disorders, including schizophrenia and cognitive impairment 8, 9 . We previously found an association between the burden of large deletions and neurodevelopmental phenotypes in a Northern Finnish population cohort, and established that several of these deletions represent founder mutations, carried on haplotypes shared identically by descent 10 . We hypothesized that some smaller deletions might be sufficiently increased in frequency in Northern Finland to enable the detection, by analyses of single variants using currently available study samples, of associations to schizophrenia and other neurodevelopmental phenotypes that are particularly frequent in this region. We found that the enrichment of a rare chromosome 22q11.22 deletion in the Northern Finnish sub-isolates enabled analyses suggesting that TOP3B, which is wholly contained in the deletion, is a risk gene for neurodevelopmental disorders.
TOP3B encodes the DNA topoisomerase III β. Our biochemical investigations of TOP3β revealed functions for this protein that could explain the phenotypic effect of its deletion. In particular, it was markedly and unexpectedly associated with FMRP, an RNA binding protein that normally inhibits the translation of neuronal mRNAs 11, 12 . The deregulated expression of these mRNAs, in the absence of this protein, is the molecular defect underlying fragile X mental retardation syndrome 13 (OMIM #300624). The process through which FMRP-containing mRNPs form remains ill-defined; however, recent investigations of the functional effect of the highly pathogenic I304N FMR1 missense mutation suggest that protein-protein interactions may contribute to the recruitment of FMRP to its target mRNAs 14 .
Our results suggest a mechanism for such a recruitment. Tudor domain-containing protein 3 (TDRD3), which itself binds to the exon junction complex (EJC) 15 deposited on newly spliced mRNAs, mediated the concomitant integration of TOP3ββ and FMRP into mRNPs. Our finding of TOP3β topoisomerase activity on RNA substrates suggests that it is involved in the metabolism of FMRP-bound mRNAs. Together with the results from genetic analyses of the Northern Finnish 22q11.22 deletion and from independent investigations of de novo TOP3B mutations [16] [17] [18] , this biochemical evidence suggests that this protein has an important role in neurodevelopment.
RESULTS

Identification of deletions enriched in Northern Finland
Using genome-wide single nucleotide polymorphism (SNP) arrays, we searched for deletions enriched in the Northeastern sub-isolates compared with the rest of Finland in representative samples from each population (sub-isolate population sample, n = 173 individuals; whole Finland population sample, n = 1,586 individuals) 19, 20 (Online Methods and Supplementary Table 1 ). To minimize false positives, we considered only deletions >20 kb in length, detected with ≥10 probes. We identified, in the combined samples, 5,313 putative deletions (5,004 heterozygous, 309 homozygous) comprising 1,041 distinct genomic loci, with a mean size of 89.4 kb.
Two deletion loci, on chromosomes 4q12 and 22q11.22, displayed significantly higher frequencies in the sub-isolate population sample than in the whole Finland population sample (P < 0.001 after 10,000 permutations), were in Hardy-Weinberg equilibrium and were confirmed by manual inspection of intensity distribution plots (Supplementary Fig. 1 ). The 4q12 deletion (181.7 kb) occurred in 6 of 173 individuals from the sub-isolate population sample and was not observed in the whole Finland population sample (P = 8.7 × 10 −7 , Fisher's exact test), whereas the 22q11.22 deletion (243.9 kb) occurred in 18 of 173 individuals from the sub-isolate population sample and in only 1 of 1,586 individuals from the whole Finland population sample (P = 8.55 × 10 −18 , Fisher's exact test).
Shared SNP haplotypes among deletion carriers indicated a single ancestral origin for each deletion. Carriers of the 4q12 deletion shared a 2.248-Mb haplotype (248 kb proximal and 2.0 Mb distal to the deletion), whereas carriers of the 22q11.22 deletion shared a 289-kb haplotype (167 kb proximal and 122 kb distal to the deletion). The presence of the shared 4q12 and 22q11.22 haplotypes among Finnish non-carriers of the deletions (population frequencies of 1.1% and 13.0%, respectively, assuming full linkage disequilibrium between their proximal and distal portions) suggests that both deletions arose relatively recently.
Neither the 4q12 deletion nor the shared haplotype in this region overlapped with known genes. The 240-kb 22q11.22 deletion lies in the 1.4-2.1-Mb distal 22q11.2 microdeletion syndrome region 21 . Several studies have implicated this region, ~400 kb telomeric to the region deleted in velocardiofacial syndrome 22 , in both schizophrenia and developmental delay 9, 23, 24 . The deletion described here encompasses two possible genes: TOP3B, a stable protein-coding gene predicted by all algorithms, with an unambiguous genomic position, and IGLV2-14, a predicted transcript of unknown function whose position has shifted between different genome builds and that shares sequence homologies with immunoglobulin variants. Two complementary low-copy repeats (chr22:20638870-20642866 and npg a r t I C l e S chr22:20904962-20908959) flank the 22q11.22 deletion and likely facilitated its formation (Fig. 2a) .
Association of the 22q11.22 deletion with schizophrenia To assess whether the increased frequencies of the 4q12 and 22q11.22 deletions in the Northeastern sub-isolate are related to risk for neurodevelopmental disorders, we compared previously genotyped samples: 185 individuals diagnosed with schizophrenia (sub-isolate schizophrenia sample 25 ) with 747 unscreened controls (sub-isolate control sample). The 22q11.22 deletion showed significantly increased frequency in the sub-isolate schizophrenia sample (odds ratio = 1.84, P < 0.03), whereas the 4q12 deletion showed no such difference (P = 0.14) ( Table 1) . We also assessed the association between the 22q11.22 deletion and schizophrenia in case-control samples from other parts of Finland and from elsewhere in Europe, using large samples, given the rarity of the deletion outside of the sub-isolate (whole Finland schizophrenia sample 23 , 467 cases; whole Finland control sample, 11,124 controls; International Schizophrenia Consortium (ISC) and Swedish Schizophrenia Consortium (SSC) 26 , 9,176 cases and 9,529 controls). The deletion displayed nominal association with schizophrenia in the whole Finland samples (odds ratio = 2.63, P = 0.008, after controlling for genomic inflation, λ = 1.20), but not in the non-Finnish samples, although the effect was in the same direction (odds ratio = 2.17, P = 0.12; Table 1 ). The combined estimate of significance was P = 0.007 (odds ratio = 1.84, 95% confidence interval = 1.18-2.87), with no heterogeneity of effect observed between the three samples.
Association of the 22q11.22 deletion with cognitive impairment We analyzed the relationship between the 4q12 and 22q11.22 deletions and seven neurodevelopmental phenotypes evaluated previously with respect to large deletions in 4,872 genotyped members of the Northern Finland 1966 Birth Cohort (NFBC1966) 10 , a geographically representative population cohort drawn from the Northeastern Figure 2 The 22q11.22 deletion covers about 240 kb, is present in homozygous form in individuals diagnosed with schizophrenia and/or cognitive deficits, and results in dose-dependent reduction in TOP3β. (a) A schematic representation of 22q11.2 (17-22.0 Mb) depicts the distinct regions containing the deletions implicated in velocardiofacial syndrome and the distal 22q11.22 deletion syndrome; the latter region includes the 240-kb 22q11.22 deletion. Orange bars depict known disease-related genes (based on OMIM), as well as genes relevant for the current study. Gray bars represent low copy repeats associated with the deletions in this region, and blue bars show the most common syndrome-related deletions 18 and the 240-kb 22q11.22 deletion. The SNPs defining the breakpoint are marked above the deletion. The breakpoint region between the SNPs is marked with dashed lines. The deletion is flanked by two complementary low-copy repeats (gray bars). The genes located on the deletion region are presented below the deletion, which incorporates the full extent of TOP3B and IGLV2-14. Genomic positions are according to hg build 36. (b). Four individuals with homozygous 22q11.22 deletions, all of whom displayed schizophrenia and/or intellectual impairment, were members of three pedigrees from Northern Finland. The pedigrees, which include two documented consanguineous matings, were presumed to descend from a common ancestor (dashed line) based on the common 22q11.22 haplotype observed among all of the homozygous deletion carriers. (c) TOP3B mRNA levels differed among non-carriers, heterozygous carriers and homozygous carriers of the 22q11.22 deletion. The expression level of TOP3β in non-carriers (269.99, 95% confidence interval = 249.18-290.79) was twice that of heterozygotes (127.61, 95% confidence interval = 103.92-151.30), and homozygous deletion carriers had no detectable transcript. Schizophrenia is associated with cognitive impairments and this association may reflect a common genetic basis for these phenotypes 27 . Given the observed association of the 22q11.22 deletion with both schizophrenia and cognitive impairment, we evaluated cognitive performance in relation to both diagnosis and deletion status in 566 schizophrenic subjects (19 deletion carriers and 547 noncarriers), each of whom was the proband in a family from the Finnish schizophrenia family study (comprising the majority of the individuals in the sub-isolate and whole Finland schizophrenia samples). Deletion carriers performed worse than non-carriers in tests assessing verbal memory after short delay (B = −1.5, P = 0.03) and showed a similar trend for other measures, although not reaching statistical significance (P > 0.05; Supplementary Table 2 ). In the pedigrees of which the 19 deletion carriers were members, we observed no apparent segregation with neurodevelopmental phenotypes of the 22q11.22 deletion in heterozygous form (Supplementary Fig. 2 ), as expected given the magnitude of the effects observed in the association analyses.
We identified, in NFBC1966 and the sub-isolate schizophrenia sample, four homozygous carriers of the 22q11.22 deletion, three of whom descended from consanguineous matings (Fig. 2b) . All four individuals displayed cognitive impairment, ranging from poor performance on tests of executive function and information processing to moderate mental retardation. Two of them were also diagnosed with schizophrenia. npg a r t I C l e S TOP3b expression is disrupted among 22q11.22 deletion carriers Given the limited genomic information and lack of prior genetic evidence relating to IGLV2-14, we chose to focus on TOP3B. Prior studies have suggested that de novo TOP3B mutations may contribute to neurodevelopmental disorders 16, 17 , and we hypothesized that disruption of this gene could account for the observed phenotypic effects of the 22q11.22 deletion. Microarray analysis in 65 individuals (51 non-carriers, 12 heterozygous carriers, and 2 homozygous carriers drawn from 18 families of the Finnish schizophrenia family study) confirmed the simple dosage-dependent effect of the deletion on TOP3B expression (probe 4900386; Fig. 2c) .
The deletion had no genome-wide significant effect on mRNA levels of other genes, either in 22q11.22 or elsewhere in the genome. However, 813 genes (858 of 9,872 probes) showed nominal difference in mRNA levels between deletion carriers and non-carriers (P < 0.05). From this set of 813 genes, we evaluated whether any functional gene category, plausibly affected by the downregulation of TOP3β, would be enriched among deletion carriers compared with non-carriers. Genes involved in two related categories, translation and ribosomal complexes, displayed a 3.1-and a 2.8-fold enrichment, respectively (P = 6.2 × 10 −8 and 2.8 × 10 −10 ; Supplementary Table 3 ), suggesting that the 22q11.22 deletion may exert its phenotypic effect via disturbed translational regulation. We were unable to detect an enrichment of differentially expressed FMRP target genes in deletion carriers 12 (data not shown). For the majority of the FMRP target genes (458 of 843), expression levels in peripheral blood were below the threshold for detection. These 458 undetectable genes were, in contrast with the 385 detected genes, overrepresented in gene categories related to neuronal functioning, suggesting that this negative result may reflect our lack of the most biologically relevant tissues for this analysis.
A complex of TOP3b, TDRD3 and FMRP binds early mRNPs To gain insight into the cellular function of TOP3β, we generated a stable cell line that expressed N-terminally FLAG and HA (FLAG/HA)-tagged TOP3β. Immunoprecipitation with antibody to FLAG revealed an interaction of TOP3β with TDRD3 and FMRP (Fig. 3a) . These proteins co-purified in an RNAse-insensitive manner, illustrating a direct, rather than RNA-mediated, interaction. TDRD3 is a multi-domain protein that, in addition to its EJC-binding motif (EBM), contains an N-terminal oligonucleotide/oligosaccharide binding fold domain (NTD) of unknown function and a C-terminal FMRP-interacting motif (FIM) 16, 17 . TOP3β bound to the NTD ( Supplementary Fig. 3a-c) , suggesting that TDRD3 is a bridging factor in a heterotrimeric TOP3β-TDRD3-FMRP (TTF) complex (Supplementary Fig. 3d ). Immunoprecipitation of TOP3β also resulted in the RNAse-sensitive co-purification of the EJC component MAGOH and the cytosolic poly(A)-binding protein PABPC1 (Fig. 3a) , suggesting that TTF is associated with spliced mRNPs. TTF exists in mouse brain lysates and NSC-34 cells, indicating that it is present in neuronal cells ( Fig. 3b and Supplementary Fig. 3e ). 5) . (e) TOP3β formed a covalent tyrosyl-5′-phosphodiester bond with RNA. Cleavage reactions using the indicated amounts of TOP3β were performed as in c, except that 3′-[ 32 P]-labeled RNA was used. Formation of the TOP3β-RNA covalent complex was monitored by denaturing SDS-PAGE and autoradiography (top). As a control, TOP3β protein was detected by western blot (bottom). (f) The TOP3β-RNA covalent complex was present in cellular extracts. Proteins bound to polyadenylated RNAs were affinity-purified by oligo(dT) cellulose as described in e, except that RNAse A treatment was performed not in the extract, but after elution from the column. This treatment revealed the enrichment of a high molecular weight species migrating above TOP3β that was detected by FLAG antibody and that was sensitive to RNAse treatment, indicating that it represents covalent complexes between FLAG/HA-TOP3β and RNA. SDS-PAGE of input (lane 1) and eluates either untreated (lane 2) or treated with RNAse (lane 3) were analyzed by and western blotting. Proteins of interest were immunodetected using the indicated antibodies. All images are representative of at least three independent experiments; full-length blots and gels are presented in Supplementary Figure 8 .
a r t I C l e S FMRP and TDRD3 are nucleo-cytoplasmic shuttling proteins and localize predominantly to the cytosol under steady-state conditions 14, 28 . The identification of TOP3β as an interactor of these proteins prompted us to analyze its subcellular distribution. Immunofluorescence microscopy, expression of GFP-tagged fusion protein and subcellular fractionation all indicated that TOP3β was also mostly cytosolic ( Fig. 3c and Supplementary Fig. 4a,b) . In addition, following arsenite treatment or strong overexpression, TOP3β colocalized with TDRD3 and FMRP in cytosolic foci reminiscent of stress granules, storage sites of translationally silenced mRNAs 29 ( Fig. 3c and Supplementary Fig. 4c,d) . Treatment of cells with the nuclear export inhibitor leptomycin-B or deletion of the putative nuclear export signal shifted GFP-TOP3β to the nucleus ( Supplementary Fig. 4e-g ). Thus, all components of the TTF complex exhibited similar intracellular localization and trafficking. To test whether TOP3β directly associates with mRNAs, we purified mRNAbound proteins using oligo(dT)-cellulose and captured TOP3β, along with FMRP and PABPC1, in an RNAse-sensitive manner (Fig. 3d) . In a vice versa experiment, we performed ultraviolet crosslinking and immunoprecipitation and found that cellular RNAs efficiently crosslinked to FLAG/HA-TOP3β (Fig. 3e) . Our results suggest that TOP3β is a component of cytosolic mRNPs.
TOP3b is catalytically active on RNA TOP3β is a type IA topoisomerase that catalyzes transient breakage of a DNA strand by reversible trans-esterification between an active site tyrosyl and a DNA 5′-phosphoryl group 30 . Cleaved intermediates can be released by SDS denaturation of the enzyme during its catalytic cycle (Fig. 4a) . The ability of TOP3β to directly bind RNA (Fig. 3e) encouraged us to test whether TOP3β might be active on RNA substrates. Indeed, the addition of RNA inhibited cleavage of 5′-labeled DNA by recombinant TOP3β (Fig. 4b) , indicating that both molecules compete for the same active site (Fig. 4c) . In addition, incubation of TOP3β with 5′-labeled RNA resulted in a specific cleavage product (Fig. 4d) . The formation of covalent complexes of TOP3β and 3′-labeled RNA was consistent with a 5′-phosphotyrosyl intermediate (Fig. 4e) .
Notably, we observed a high molecular weight smear in western blot analysis of FLAG/HA-TOP3β oligo(dT)-purified from cellular extracts (Fig. 3d) . Reasoning that this smear might represent covalent complexes between FLAG/HA-TOP3β and RNA, we eluted oligo(dT)-purified FLAG/HA-TOP3β from the column and treated the eluate with RNAse (Fig. 4f) . RNAse treatment eliminated the FLAG-positive high molecular weight species, suggesting that TOP3β is active on mRNA substrates in vivo.
TTF-containing mRNPs are associated with polyribosomes
To analyze whether TTF-bound mRNPs are associated with the translation machinery, we first purified translation factors from HeLa cells (Fig. 5a) . As reported for FMRP 31 , TDRD3 and TOP3β were present in crude ribosomal pellets, but dissociated following high-salt treatment (Fig. 5b) , suggesting that they are components of translating mRNPs.
Western blot analysis of polysome gradient centrifugation from stable FLAG/HA-TDRD3 cell extracts revealed that FLAG/HA-TDRD3 and endogenous TOP3β co-migrated with FMRP in polysomal fractions in an RNAse-sensitive manner (Fig. 5c) , indicating that part of the TTF-bound mRNP pool undergoes translation. This observation is noteworthy considering the binding of TDRD3 to the EJC 15 , as the latter is thought to be removed from the mRNA during the first round of translation 32 . A hallmark of mRNPs that participate in this 'pioneer round' of translation is their association with the nuclear cap binding proteins CBP20 and CBP80 instead of eIF4E 32 . Immunoprecipitation of TTF-containing mRNPs via FLAG/ HA-TDRD3 revealed their binding to CBP20 and CBP80, but not to (Fig. 5d) , suggesting that TTF is a component of mRNPs undergoing the pioneer round of translation.
TTF recruitment to mRNPs requires the TDRD3 Tudor domain
To dissect the mechanisms leading to TTF formation and integration into mRNPs, we generated TDRD3-mutants in which individual protein-protein interactions were disrupted (Fig. 6a) . We established stable cell lines expressing FLAG/HA-tagged versions of these mutants and analyzed them by immunoprecipitation and polysome gradient centrifugation. Wild-type TDRD3 formed the TTF complex (Fig. 6b) and became integrated into polysome-bound mRNPs ( Supplementary  Fig. 5a ). Deletion of the binding sites for FMRP (TDRD3 ∆FIM ) or TOP3β (TDRD3 ∆NTD ) resulted in the loss of the respective protein from TTF ( Fig. 6b and Supplementary Fig. 5b) . However, integration of the remaining binary complexes into mRNPs and polysomes was unaffected ( Fig. 6b and Supplementary Fig. 5a,b) , indicating that the recruitment of TDRD3 to the EJC can occur independently of TTF formation. Mutation of the EBM (TDRD3 EBMmut ), however, abolished integration of TDRD3 into mRNPs, and binding of TOP3β and FMRP were unaffected (Fig. 6b and Supplementary Fig. 5a ). Thus, formation of the TTF complex occurs before TDRD3 is tethered to the EJC.
Lastly, we analyzed a missense mutation of the Tudor domain (TDRD3 TDRmut ) that impairs the recognition of asymmetrically dimethylated arginine (aDMA) modifications in the C-terminal domain of RNA polymerase II (RNAPII) and in the tails of histones H3 and H4 at the transcription start site (TSS) 33, 34 . As several mRNA processing factors are recruited to the nascent transcript via the RNAPII C-terminal domain, we reasoned that TDRD3 might follow a similar route. Indeed, TDRD3 TDRmut showed strongly reduced association of TDRD3 with mRNPs ( Fig. 6b and Supplementary  Fig. 5a ). Although this mutation did not affect the assembly of a TOP3β-TDRD3 heterodimer, it diminished the recruitment of FMRP (Fig. 6b) . Thus, the generation of TTF-containing mRNPs requires the recognition of aDMA by TDRD3. Although FIM and EBM reside outside of the Tudor domain 14, 15 , we wanted to exclude the possibility that the latter contributes to FMRP or EJC binding, as aDMA modifications have been reported for FMRP and other mRNP components 35 . We incubated purified TDRD3 with cellular extracts and analyzed the samples for bound FMRP and MAGOH, observing no differences between wild-type and Tudor mutant protein (Fig. 6c) . This finding was specific, as TDRD3 EBMmut failed to associate with MAGOH (Fig. 6c) . Thus, mutating the Tudor domain per se did not influence the binding of TDRD3 to FMRP or the EJC. Instead, the defect of TDRD3 TDRmut in TTF formation and mRNP incorporation appears to be a consequence of its impaired binding to aDMAmodified histones and/or RNAPII. : FLAG  FLAG/HA-TDRD3   --------+  +  --------+  +  --------+  +  ----- The indicated mutants were immunoprecipitated and co-precipitated proteins were analyzed by western blotting. Note that the residual FMRP signal was RNAse sensitive for TDRD3 ∆FIM , but not for TDRD3 TDRmut , indicating that in the latter case, the TTF complex was formed, albeit with an efficiency lower to that of wild-type TDRD3 ( Supplementary Fig. 5c ). npg a r t I C l e S Formation of TTF containing mRNPs requires TDRD3 Our results suggest a mechanism for the concomitant integration of TOP3β, TDRD3 and FMRP into mRNPs. To investigate whether this is the only pathway for the biogenesis of mRNPs containing TOP3β and FMRP, we used a cell line carrying a deletion encompassing TDRD3 (ref. 36) . Gradient centrifugation revealed that the association of TOP3β with polysomes was diminished in these TDRD3-deficient cells (Fig. 6d) . However, following transfection of FLAG/HA-TDRD3, TOP3β was redistributed into the polysomal fractions. Thus, TDRD3 is necessary and sufficient for the recruitment of TOP3β to mRNPs. Overexpressed TDRD3 EBMmut was not associated with polysomes and consequently failed to increase the amount of polysomal TOP3β ( Fig. 6d and Supplementary Fig. 6a ), indicating that the EJC is the only docking platform for TTF on mRNPs.
In contrast, FMRP associated with polysomes in TDRD3-deficient cells (Supplementary Fig. 6b ). This observation suggests that TTFcontaining mRNPs constitute only a subpopulation of the FMRPbound pool and implies that alternative routes exist for integrating FMRP into mRNPs. Thus, we analyzed whether the presence of TDRD3 is a prerequisite for recruitment of FMRP into a specific, TTF-containing mRNP subpopulation. We transfected TDRD3-deficient cells with either GFP-TOP3β alone or together with FLAG/HA-TDRD3 variants and assayed them for TTF and mRNP formation via GFP immunoprecipitation. GFP-TOP3β association with FMRP and mRNPs was entirely dependent on co-transfected wild-type TDRD3 (Fig. 6e) . In contrast, co-transfection of FLAG/ HA-TDRD3 ∆FIM enabled the formation of mRNPs containing GFP-TOP3β, but these mRNPs were entirely devoid of FMRP (Fig. 6e) . Together, these data indicate that TDRD3 is essential for the integration of FMRP into the subpopulation of mRNPs that contain the TTF complex.
DISCUSSION
Our finding of association between neurodevelopmental disorders and a 22q11.22 deletion, vastly increased in frequency in Northern Finnish sub-isolates and occurring on a single haplotype, demonstrates the value of such populations for identifying variants with a large effect on common phenotypes. Projects underway that aim to comprehensively genotype a large proportion of the Finnish population 37 should be able to exploit such enrichment of functional variants to identify a wide range of trait associations that, in most populations, could require infeasibly large samples. As with the 22q11.22 deletion, this enrichment could also facilitate the identification of homozygotes in whom the phenotypic effect of such variants is more extreme.
Large-scale implementation of this strategy for identifying highimpact variants must address the concern that standard methods of controlling for population stratification may not work well for rare variants 38 . Such stratification is unlikely to be a major issue in our study for several reasons. First, in Northern Finland, the 22q11.22 deletion has an allele frequency of ~3-5% and is therefore not a rare variant. Second, stratification is of less concern in populations in which substructure has a clear geographical basis 38 and fine-grained information is available about the geographical origin of the study subjects, as is the case in multiple Finnish cohorts; several studies have shown the high degree of correlation in such cohorts between geographical origin and measures of stratification obtained from genome wide SNP data 2, 39 . In addition, implementation of newly developed methods for correcting for stratification at rare variants 40 may facilitate application of our strategy to a wider range of populations.
The population effect in Northern Finland of the 22q11.22 deletion is likely much greater than has been recognized given its frequency and association with quantitative measures of neurocognitive impairment. The predominant effect of the 22q11.22 deletion appears to be on measures of neurocognitive function rather than on risk for specific diagnostic entities, as evidenced by the range of phenotypes displayed by the homozygous deletion carriers and in the population cohort in which we observed trait associations. It may be feasible to more precisely delineate the phenotypic effect of this deletion, as well as other deletions that could have a similar effect, by obtaining more complete neurocognitive assessments in larger samples from the Northern Finland population. The accumulation of deletion genotype-phenotype associations that cut across classical disease categories has the potential to enhance our understanding of mechanisms underlying disorders of brain and behavior. For example, our results suggest that large-scale investigations of deletions in schizophrenia study samples phenotyped for neurocognitive measures may contribute to the genetic dissection of this phenotypically heterogeneous syndrome.
The phenotypic effect of the 22q11.22 deletion likely derives from its effect on TOP3B; the deletion directly disrupts this gene, downregulates its mRNA levels and does not appear to alter transcript levels of genes outside the deletion region. This interpretation is consistent with findings from a recent report of a single individual, of unspecified ethnic origins, who demonstrated speech delay and minor physical abnormalities and carried a deletion that appears to be identical to the one presented here 18 . Analysis of animal models with a genetically equivalent mutation may help clarify whether TOP3β is important in synaptic plasticity.
Although the deletion also incorporates IGLV2-14, and we cannot exclude the possibility that its loss contributes to the phenotypes that we observed, it is merely a predicted transcript of unknown function, for which no independent mutations have been reported in either the literature or databases. In contrast, recent surveys of de novo mutations have yielded both direct and indirect genetic evidence suggesting that TOP3B missense variants contribute to schizophrenia and autism spectrum disorders 16, 17 . The independent forms of genetic evidence represented by the deletions and de novo variants are complementary and, taken together, strengthen the suggestion that TOP3B is important in neurodevelopment.
Biochemical analysis revealed that TOP3β is part of a heterotrimeric TTF complex. An accompanying study found that TOP3β interacts with FMRP via TDRD3 and that TOP3β modifies FMR1 function in the Drosophila neuromuscular junction synapse formation 41 . Our data suggest a stepwise model for TTF formation (Supplementary Fig. 7a ). TDRD3 reads aDMA marks on histones and RNAPII 33, 34 , a process that recruits a TDRD3-TOP3β heterodimer to the TSS. After binding of FMRP, the resulting heterotrimeric complex transfers to an EJC on the nascent transcript. In this scenario, the recruitment of FMRP into mRNPs does not require direct binding of FMRP to mRNA. Instead, recognition of aDMA marks at the TSS by TDRD3 determines whether the resulting transcript is a target for FMRP. Consistent with this conclusion, the genes bound by TDRD3 at their TSS overlapped significantly with those that acquire FMRP as a component of their mRNPs (P < 0.0001; Supplementary Fig. 7b ). Our data further show that other routes of FMRP recruitment to mRNPs must exist, as FMRPcontaining mRNPs still form in TDRD3-deficient cells, and our model does not rule out that FMRP, after being bound to the EJC, directly contacts its target mRNAs, offering an explanation for the observation that FMRP binding sites are dispersed throughout the coding regions on many transcripts 12, 42 . In addition, this model predicts that, in the absence of TOP3β, mRNPs that normally contain TTF are loaded only with a TDRD3-FMRP heterodimer (Supplementary Fig. 7a ).
npg a r t I C l e S
The fate of the EJC-bound TTF complex and the functional consequences of this interaction are currently unknown. TTF-containing mRNPs associate with CBP20/80, but not with eIF4E, suggesting a role for TTF during the pioneer round of translation 32 . EJC-associated factors such as the RNA surveillance complex or the protein kinase S6K1 rigorously control this step. The latter is, similar to the TTF complex, specifically recruited to the EJC, increasing the translational efficiency of the pioneer round 43 . S6K1 phosphorylates FMRP and is an effector of the mammalian target of the rapamycin (mTOR) pathway, which controls activity-dependent translation in neurons 44 . The EJC might therefore serve as a molecular scaffold to integrate the actions of FMRP and mTOR in regulated neuronal translation.
We note that the TTF complex bears marked similarity to the BLM-TOP3α-RMI1 complex 45 , which has been implicated in the catalytic dissolution of replication-induced DNA four-way junctions 46 . Similar four-way junctions present in RNA can be interconverted into kissing complexes, which are known FMRP-binding sites 47, 48 . Our data therefore raise the possibility that TOP3β remodels FMRP binding sites. Nevertheless, other functions of TOP3β in mRNA metabolism, or even in completely unrelated cellular processes, also appear feasible and deserve further investigation.
The identification of TTF uncovered an unexpected biochemical link between Fragile X syndrome patients and TOP3B deletion carriers. This discovery raises two alternative scenarios. First, neurodevelopmental disorders traditionally considered distinct may share common etiologies; under this scenario, the dysregulation of TTF-containing mRNPs may underlie the overlapping neurocognitive impairment phenotypes observed in Fragile X syndrome and schizophrenia. Alternatively, different mutations in TOP3B that affect different functions of the gene result in different forms of psychopathology, and it is possible that deletion of this gene contributes to neurodevelopmental phenotypes through as yet unidentified non-FMRP pathways.
Future biochemical and enzymatic analyses of pathogenic TOP3B missense mutations may enable us to reject one of these scenarios. However, the second scenario implies a greater level of specificity and certainty with respect to the definition and etiology of neuropsychiatric syndromes than is suggested by currently available data. For example, Fragile X syndrome and schizophrenia share important phenotypic features that make it unsurprising that they could also share underlying biological processes. Deficits in working memory and other executive functions are perhaps the most salient neurocognitive features of schizophrenia 49 and are also frequently observed in Fragile X males 50 . Impairment in cognitive function is also a feature of autism spectrum disorders, and it is possible that FMRP-related abnormalities contribute to cognitive dysfunction in all of the disorders discussed here. The systematic identification of neuronal TTF mRNA targets and their functional analysis in relation to neuronal plasticity will help to clarify whether this is the case.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
The study samples. Supplementary Table 1 Sub-isolate population sample. The sub-isolate population sample consisted of 173 participants, selected from FINRISK, a periodic nationwide health survey cohort of randomly selected, representative population samples from different parts of the country focused on risk factors for chronic and non-communicable diseases 19 . The 1997 and 2007 surveys included individuals from Northeastern sub-isolate municipalities. We selected all FINRISK participants with both parents originating from the sub-isolate. Treating physicians contacted potential probands; for those who provided written informed consent, they also contacted additional family members. Independent review of materials by psychiatrists blind to the family structures led to consensus best-estimate lifetime diagnoses according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 25 .
The 566 subjects selected from the schizophrenia study were members of independent nuclear families. The sub-isolate schizophrenia sample included 171 of these individuals who originated from the Northeastern Finland sub-isolate. The whole Finland schizophrenia sample included those who originated outside of the sub-isolate (n = 395). We identified the rest of the Finnish schizophrenia subjects included in this study (14 in the sub-isolate schizophrenia sample, and 72 in the whole Finland schizophrenia sample) among participants of H2000 and NFBC1966 diagnosed with DSM III-R or DSM IV schizophrenia or schizoaffective disorder using multiple sources of information, including structured clinical interviews and medical records.
Sub-isolate control sample and whole Finland control sample. These samples are distinct from those that we used to investigate regional differences in deletion frequencies, and consist of participants of nationwide Finnish health surveys and population cohorts; NFBC1966, NFBC1986, H2000, the Cardiovascular Risk in Young Finns study (YFS), the Finnish Twin Cohort (FTC), and the Dietary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome study (DILGOM). Altogether, the cohorts comprised 11,871 individuals. Of these individuals, the sub-isolate control sample included 747 who originated from the Northeastern Finland sub-isolate, whereas the whole Finland control sample included the remaining 11,124 individuals. nFBc1966 and nFBc1986. The study subjects were members of two prospective birth cohorts consisting of 96% and 99% of all live-born children in the two most Northern provinces of Finland in 1966 and between July 1985 and June 1986 (NFBC1966 and NFBC1986, respectively) 10, 52 . NFBC1966 began with collection of prenatal clinical data on 12,068 live born children and has continued with follow-ups at multiple time points that generated a phenotype database combining information from official registers, hospital records, questionnaires and clinical examinations of the participants. Our study included 4,931 genotyped individuals from this cohort 10 : 59 with a DSM-III-R based diagnosis of schizophrenia or schizoaffective disorder, and 4,872 without such diagnoses (members of either the sub-isolate schizophrenia sample and sub-isolate control sample or whole Finland schizophrenia sample and whole Finland control sample, respectively, depending on their parents' birthplace). We also used the 4,872 controls to evaluate the relationship between the 4q12 and 22q11.22 deletions and other neurodevelopmental phenotypes previously examined in this cohort in relation to larger deletions 10 .
NFBC1986 consists of 9,340 live born children, prospectively followed since their 12th gestational week. The last follow-up to date, at age 16 (2001-2002) , included 6,645 individuals who gave consent to participate in the study. The sub-isolate control sample includes NFBC1986 individuals (n = 212) with both grandparents originating from the Northeast Finland sub-isolate 52 .
H2000. H2000 is a nationally representative cross-sectional health study carried out in 2000-2001 and includes 8,028 individuals. We selected 2,402 H2000 participants. The majority (n = 2,212) were cases and controls from a sub-study of genetic risk factors for metabolic syndrome, of whom 27 met DSM-IV diagnosis for schizophrenia or schizoaffective disorder, included as cases in the present study 53 . The remaining 190 individuals were controls in a large European schizophrenia consortium, SGENE 54 .
YFS.
YFS is a follow-up study of cardiovascular risk factors from childhood to adulthood in study participants randomly chosen from the population register and recruited from five university cities in Finland. The baseline study launched in 1980 and included 3,596 individuals. Follow-ups have occurred on average every 3 years, most recently in 2007, when participants were 27 years old. The present study included 2,308 individuals from YFS with available genome-wide association study (GWAS) data 55 .
FTc. We ascertained 1,492 individuals (one twin, chosen randomly, per pair) from the genotyped participants of the FTC. The FTC includes both monozygotic and dizygotic twins, collected in several separate phases. The older cohort included 13,888 same-sex and 8,000 opposite sex pairs with known zygosity. The younger Finnish twin cohorts, referred to as FinnTwin12 and FinnTwin16, are longitudinal studies of behavioral development and health habits of Finnish twins enrolled at ages 11-12 and 16, respectively. These cohorts included 4,913 pairs of both monozygotic and dizygotic pairs 56 . ISc. The ISC sample consisted of 3,391 schizophrenia subjects, diagnosed according to DSM-IV or ICD 10, and 3,181 controls, all of European origin. A previous publication detailed the data set and the copy number variation (CNV) calls (obtained using Birdseye), from the intensity data of the genotype probes on the Affymetrix 5.0 and 6.0 genotyping arrays 23 .
SSc. The SSC sample included individuals in Sweden hospitalized at least twice for schizophrenia since 1973 (n = 5,785). The SSC controls (n = 6,348), group matched with the cases regarding age, sex and county of residence had no hospitalization as a result of psychiatric diagnoses.
gwAS and cnV calling. Genome-wide genotyping studies used the following arrays: Illumina Human670K customBeadChip (HBCS, NFBC1986, YFS, FT TWINS, DILGOM and parts of the Schizophrenia Family Study sample), Illumina Infinium HDHuman610-Quad BeadChip (DILGOM and the majority of the H2000 sample), Illumina HumanHap300 Chip (the remainder of the schizophrenia subjects and H2000 controls, included in the SGENE consortium), Illumina HumanHap370 Chip (NFBC1966), and Affymetrix 5.0 and 6.0 genotyping arrays (ISC and SSC). We used QuantiSNP 58 and PennCNV 59 software npg to make CNV calls, employing the LogR Ratio (LogRR) and B-allele frequency (BAF) of SNP probes included in the genotyping arrays. We called CNVs independently for each cohort and carried out quality control based on graphical clustering of LogRR or BAF s.d., removing outlier samples from each cohort. In all cohorts, we excluded individuals if their LogRR or BAF s.d. were over 0.35 and 0.07, respectively, waviness factor was outside the range −0.04-0.04, and BAF drift exceeded 0.002, according to software recommendations.
We conducted a genome-wide scan for deletions (>20 kb in size) in the subisolate and whole Finland population samples, reading deletion genotypes from QuantiSNP and including only deletions with >10 probes and Bayes factor >10. To ensure reliable high-quality data, we visually inspected the intensity distributions for deletions that showed significant deviation in frequency between the sub-isolate and whole Finland samples and tested them for Hardy-Weinberg equilibrium. For the other data sets, we used deletion calls intersecting the previously identified regions on chromosomes 4 and 22. We validated the 22q11.22 in a subset of 258 individuals (19 carrying the deletion) with Sequenom MassARRAY and quantitative real-time PCR. The deletion genotypes had 100% correspondence with those from GWAS arrays.
Statistical analysis.
We discarded from the analysis breakpoints including more than 88 overlapping deletions (frequency > 5%) in the 1,759 individuals. We used PLINK software 60 to cluster individuals to sub-isolate and whole Finland groups, according to parental origin, compared the frequencies of deletions (>20 kb, at the start and end point of each deletion) between the sub-isolate population sample and the whole Finland population sample, and calculated allelic χ 2 P values. We calculated empirical P values after 10,000 permutations for each deletion breakpoint. For testing associations with schizophrenia and other traits, we used allelic Fisher exact tests and Conchran-Mantel-Haenszel statistics. gene expression analysis. Using an Illumina HumanHT-12 v4 Expression BeadChip, we generated genome-wide gene expression data for 65 individuals from 18 families of the Finnish schizophrenia family study at the FIMM Technology Centre. To study the direct effect of the 22q11.22 deletion on TOP3B, we studied its average expression levels (probe 4900386) in heterozygous carriers (n = 12 individuals), homozygous carriers (n = 2) and non-carriers (n = 51), and used R (MA-ANOVA program package) to analyze the effect of carrying this deletion on genome-wide gene expression levels, including only the 9,872 probes that showed signal above background levels in all individuals. As this analysis was exploratory, we derived q values to determine whether any of the observed significant changes occurred beyond the level of false discovery. The pathway analysis carried out for 813 genes (858 probes) showed nominal statistical difference (P < 0.05) between deletion carriers and non-carriers, using the functional annotation tool in DAVID bioinformatics resources 6.7 (ref. 61).
Antibodies. A previous publication described the primary antibody to FMRP 14 . Purchased primary antibodies included antibodies to FLAG (Sigma, A2220, 1:1,000), HA (HISS, MMS-101R, 1:1,000), GFP (Roche, 11814460001, 1:1,000), TDRD3 (Bethyl, A310-983A, 1:500), TOP3β (Abcam, ab56445, 1:500), PABPC1 (Abcam, ab21060, 1:1,000), GAPDH (Abcam, ab9485, 1:1,000), histone H3 (Abcam, ab1791, 1:1,000), rpL7 (Abcam, 72550, 1:1,000), MAGOH (Santa Cruz, sc-271405, 1:500), CBP80 (Santa Cruz, sc-271304, 1:250), CBP20 (Santa Cruz, sc-48793, 1:500), eIF2γ (Proteintech, 11162-1-AP, 1:500) and eIF4E (Abcam, ab1126, 1:250).
Plasmids and mutagenesis. We cloned cDNAs of TDRD3 (wild type or truncations) and TOP3β in a pcHA/DNA5/FRT/TO plasmid (Invitrogen) containing an N-terminal FLAG-tag (for stable cell line preparation), a pGEX-6P-1 vector containing a C-terminal 6xHis-stop sequence (for protein expression) or a pEGFP C1 vector (for immunocytochemistry or immunoprecipitation), and introduced point mutations and deletions into the individual constructs by PCR mutagenesis. cell culture, plasmid transfections. The culture medium for all cells was DMEM containing 10% fetal calf serum and 1% Pen/Strep (PAA). Stable cell line medium also contained balsticidin and hygromycin (both Invivogen); tetracycline addition (1:2,000) 5 h before harvesting induced protein expression in these cells. We carried out all transfections using Nanofectin (PAA). Generation and cultivation of HEK293 FlpTRex cell lines (Invitrogen) was according to manufacturer's instructions. The TDRD3-deficient human lung adenocarcinoma cell line VMRC-LCD was purchased from the Japanese Collection of Bioresources Cell Bank (JCRB no. JCRB0814).
Immunocytochemistry and stress treatment. For immunocytochemistry and stress treatment, we followed procedures described previously 16 . We treated cells with 50 ng ml −1 Leptomycin B for 3 h to block nuclear export.
co-immunoprecipitations.
We performed co-immunoprecipitations with 25 µl of α-FLAG M2 agarose (Sigma) or protein-G Sepharose (GE Healthcare) bound antibodies to GFP (Roche) per ml of cell extract. After adding lysis buffer (150 mM NaCl, 50 mM Tris (pH 7.5), 2.5 mM MgCl 2 and 0.5% NP-40, 0.5 mM DTT, protease inhibitors) and incubation on ice for 10 min, we cleared extracts by centrifugation (11,200 g, 10 min, 4 °C) before co-immunoprecipitation for 1 h (4 °C). Subsequent to extensive washing of the beads with lysis buffer, we eluted precipitated complexes with 1% SDS (15 min, 70 °C) and subjected them to SDS-PAGE and western blot. Dounced and cleared mouse brain homogenate (in ice-cold co-immunoprecipitation lysis buffer, see above) served for immunoprecipitations, with the indicated antibodies bound to Protein G-Sepharose (GE Healthcare).
cross-linking and immunoprecipitation (clIP).
We grew HEK293 FlpTRex-TOP3β cells or HEK293 control cells on 15-cm plates to ~90% confluency and ultraviolet cross-linked them 5 h later (254 nm, CL-1000 Ultraviolet Crosslinker). We then incubated harvested cells with lysis buffer containing protease inhibitors (50 mM HEPES (pH 7.5), 150 mM KCl, 2 mM EDTA, 0.5% NP-40, 1 mM DTT) for 10 min on ice. After lysate clearing (11,200 g, 10 min, 4 °C), we treated the samples with RNAse T1 (1:10,000, 7 min, 22 °C) (Ambion, 1,000 U µl −1 ). We cooled the extracts subsequently on ice for 5 min and incubated them with pre-equilibrated magnetic FLAG M2 agarose (Sigma, 1 h, 4 °C). We then washed the beads (50 mM HEPES pH 7.5, 300 mM KCl and 0.05% NP-40) before adding different RNAse T1 concentrations (1:100,000, 1:10,000, 1:1,000 or 1:100) and repeated the washing procedure (three times with high salt buffer (50 mM HEPES pH 7.5, 500 mM KCl, 0.05% NP40) and three times with phosphatase buffer (10 mM Tris-HCl pH.8, 100 mM KCl, 5 mM MgCl 2 and 0.2% Triton X-100)). Dephosphorylation of co-precipitated RNAs occurred within 40 min at 37 °C using Fast AP (Fermentas). We 5′-labeled RNAs on washed beads using [γ-32 P] ATP (Perkin Elmer) and PNK (Fermentas, 1 h, 37 °C). After additional washing five times with labeling buffer, we boiled the beads in SDS sample buffer and subjected eluates to gel electrophoresis (NuPAGE Bis-Tris 4-12%, Life Technologies) and subsequent western blotting on nitrocellulose. Antibodies to FLAG enabled us to detect precipitated FLAG/HA-TOP3β, and exposing the blot membrane to an X-ray film allowed the detection of the RNA. oligo(dT) pulldown. We performed oligo(dT) pulldown assays using oligo(dT) cellulose (Fluka) according to manufacturer's instructions. We analyzed the oligo(dT) bound mRNPs by SDS-PAGE and western blot as described above either after mock treatment or after digestion with RNAse A. (Qiagen).
cleavage assays. We labeled RNA (GGGAUUAUUGAACUGUUGUUCAAGCG UGGU) or DNA (GGGATTATTGAACTGTTGTTCAAGCGTGGT) oligomers at the 5′ end using [γ-32 P] ATP (Perkin Elmer) and PNK (Fermentas, 1 h, 37 °C) or at the 3′ end using [5′-32 P] pCp and T4 RNA Ligase (Fermentas, overnight at 4 °C). For cleavage assays, we incubated ~40 fmol of radiolabeled oligomers with recombinant TOP3β wild-type or active site mutant (Y336F) (amounts are indicated in the individual experiment) at 42 °C in buffer containing 40 mM HEPES pH 6.5, 10% PEG400, 40% glycerol, 1 mM MgCl2, 1 mM DTT and 10 µg ml −1 BSA for 2 min. SDS at a final concentration of 0.2% and incubation for 1 min stopped the reaction. We analyzed release of 5′ fragments on 12% UREA PAA-Gels and covalent 3′-labeled TOP3β-RNA intermediates on a 10% SDS PAA-Gel. Detection of recombinant TOP3β occurred via western blotting using antibodies to TOP3β and detection of RNAs via autoradiography. cell fractionation and gradient centrifugation. We used the Qproteome cell compartment kit (Qiagen) to prepare nuclear and cytoplasmic extracts from HeLa cells according to manufacturer's instructions. We purified translation factors as npg
